IPCA Laboratories has got import alert from US Food and Drug Administration (USFDA) for two of its manufacturing plants. According to USFDA, IPCA Labs' unit in Pithampura (MP) and Piparia (Silvassa) have failed to meet GMP.
This is the third import alert for the company. Earlier in January this year, US regulator had banned imports from a Madhya Pradesh manufacturing plant of Ipca, citing violations of standard production practices.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
